High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis

BMC Infectious Diseases - Tập 13 Số 1 - 2013
Fabrícia Alvisi de Oliveira1, Carla Vanessa Oliveira Silva1, Nicole Prata Damascena1, Rodrigo Oliveira Passos1, Malcolm S. Duthie2, Jeffrey A. Guderian2, Ajay Bhatia2, Tatiana Rodrigues de Moura1, Steven G. Reed2, Roque Pacheco de Almeida3, Amélia Ribeiro de Jesus3
1Molecular Biology Laboratory, Hospital Universitário – Universidade Federal de Sergipe, Rua Claudio Batista s/n, Bairro Sanatório, Aracaju, Sergipe, 49060-10, Brazil
2IDRI- Infectious Disease Research Institute, Seattle, WA, 98102, USA
3Instituto de Investigação em Imunologia (iii) – Institutos Nacionais de Ciência e Tecnologia (INCT), CNPq, São Paulo, Brazil

Tóm tắt

AbstractBackgroundSoluble CD40 ligand (sCD40L) and matrix metalloproteinase 9 (MMP-9) are inflammation markers and have been poorly described in infectious disease. In this prospective study, we describe the sera kinetics of these two molecules in the course of treatment follow up in human visceral leishmaniasis (VL).MethodsSera from VL patients were collected before and during follow up of regular Antimony treatment. sCD40L and MMP-9 were measured by Luminex assay. Paired analysis by Wilcoxon signed test was used for comparison of values of the same subjects before and after initiation of treatment. Correlations between clinical data and parasite load with the serum levels of sCD40L and MMP-9 were performed by Spearman test. Tests were considered statistically significant if the probability of a type I error was less than 5% (p-value < 0.05).ResultsWhile sCD40L and MMP-9 were not observed in sera from non endemic controls which are at low risk ofLeishmania chagasiinfection, elevated levels were observed in sera from VL patients, and an increase in sCD40L and MMP-9 levels were detectable during the follow-up of VL patients undergoing antimony treatment. sCD40L levels were also high in individuals living in endemic settings at high risk of infection (endemic controls). Additionally, negative correlations were found between spleen sizes and MMP-9 before treatment and sCD40L at day 15 of treatment. Negative correlations were also found between parasite load with both sCD40L and MMP-9.ConclusionSerum sCD40L and MMP-9 are identified as new and simple biomarkers in two situations: (i) monitoring the success of therapy and (ii) predicting favorable clinical outcome of human VL.

Từ khóa


Tài liệu tham khảo

Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD: Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest. 1985, 76: 2066-2069. 10.1172/JCI112209.

Rai AK, Thakur CP, Singh A, Seth T, Srivastava SK, Singh P, Mitra DK: Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS One. 2012, 7: e31551-10.1371/journal.pone.0031551.

Goto H, Prianti M: Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 2009, 51: 241-246. 10.1590/S0036-46652009000500002.

Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E: Serum interferon activity of patients with leishmaniasis. Braz J Med Biol Res. 1989, 22: 1485-1487.

Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WD: Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis. 1992, 165: 535-540. 10.1093/infdis/165.3.535.

Carvalho EM, Bacellar OA, Reed S, Barral A, Rocha H: Visceral leishmaniasis: a disease associated with inability of lymphocytes to activate macrophages to kill leishmania. Braz J Med Biol Res. 1988, 21: 85-92.

Bacellar O, D'Oliveira A, Jeronimo S, Carvalho EM: IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000, 12: 1228-1231. 10.1006/cyto.2000.0694.

Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM: Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest. 1993, 92: 2626-2632. 10.1172/JCI116878.

Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP: Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis. 2003, 188: 458-464. 10.1086/376510.

Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, Salotra P: Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS One. 2010, 5: e10107-10.1371/journal.pone.0010107.

McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA: CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. J Immunol. 1998, 160: 1701-1707.

van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 2000, 67: 2-17.

Subauste CS: CD40 and the immune response to parasitic infections. Semin Immunol. 2009, 21: 273-282. 10.1016/j.smim.2009.06.003.

Mathur RK, Awasthi A, Saha B: The conundrum of CD40 function: host protection or disease promotion?. Trends Parasitol. 2006, 22: 117-122. 10.1016/j.pt.2006.01.003.

Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B: Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med. 2004, 10: 540-544. 10.1038/nm1045.

Subauste CS, Wessendarp M, Sorensen RU, Leiva LE: CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. J Immunol. 1999, 162: 6690-6700.

Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immun. 1996, 3: 283-289.

Habib M, Noval Rivas M, Chamekh M, Wieckowski S, Sun X, Bianco A, Trouche N, Chaloin O, Dumortier H, Goldman M, Guichard G, Fournel S, Vray B: Cutting edge: small molecule CD40 ligand mimetics promote control of parasitemia and enhance T cells producing IFN-gamma during experimental Trypanosoma cruzi infection. J Immunol. 2007, 178: 6700-6704.

Schonbeck U, Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001, 58: 4-43. 10.1007/PL00000776.

Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996, 156: 3952-3960.

Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D: Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem. 1997, 272: 911-915. 10.1074/jbc.272.2.911.

Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995, 25: 1749-1754. 10.1002/eji.1830250639.

Haanen JB, Schumacher TN: Vaccine leads to memory loss. Nat Med. 2007, 13: 248-250. 10.1038/nm0307-248.

Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem. 1999, 274: 21491-21494. 10.1074/jbc.274.31.21491.

Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, Basaraba RJ, Orme IM, Matrisian LM, Izzo AA: Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun. 2006, 74: 6135-6144. 10.1128/IAI.02048-05.

Gutierrez FR, Lalu AA, Mariano FS, Milanezi CM, Cena J, Gerlach RF, Santos JE, Torres-Duenas D, Cunha FQ, Schulz R, Silva JS: Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection. J Infect Dis. 2008, 197: 1468-1476. 10.1086/587487.

Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003, 348: 1104-1111. 10.1056/NEJMoa022600.

Tousoulis D, Androulakis E, Papageorgiou N, Briasoulis A, Siasos G, Antoniades C, Stefanadis C: From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand. Trends Cardiovasc Med. 2010, 20: 153-164. 10.1016/j.tcm.2010.12.004.

Lorente L, Martin MM, Varo N, Borreguero-Leon JM, Sole-Violan J, Blanquer J, Labarta L, Diaz C, Jimenez A, Pastor E, Belmonte F, Orbe J, Rodriguez JA, Gomez-Melini E, Ferrer-Aguero JM, Ferreres J, Lliminana MC, Paramo JA: Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care. 2011, 15: R97-10.1186/cc10104.

Sipsas NV, Sfikakis PP, Kontos A, Kordossis T: Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clin Diagn Lab Immunol. 2002, 9: 558-561.

Costa JD, de Melo AC N, Vermelho AB, Meirelles N, Porrozzi R: In vitro evidence for metallopeptidase participation in hepatocyte damage induced by Leishmania chagasi-infected macrophages. Acta Trop. 2008, 106: 175-183. 10.1016/j.actatropica.2008.03.006.

Melo GD, Marangoni NR, Marcondes M, Lima VM, Machado GF: High levels of serum matrix metalloproteinases in dogs with natural visceral leishmaniosis: a preliminary report. Vet J. 2011, 188: 243-245. 10.1016/j.tvjl.2010.03.017.

Schulz A, Mellenthin K, Schonian G, Fleischer B, Drosten C: Detection, differentiation, and quantitation of pathogenic leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol. 2003, 41: 1529-1535. 10.1128/JCM.41.4.1529-1535.2003.

Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999, 5: 1135-1142. 10.1038/13459.

Palombo D, Maione M, Cifiello BI, Udini M, Maggio D, Lupo M: Matrix metalloproteinases. Their role in degenerative chronic diseases of abdominal aorta. J Cardiovasc Surg (Torino). 1999, 40: 257-260.

Lima ID, Queiroz JW, Lacerda HG, Queiroz PV, Pontes NN, Barbosa JD, Martins DR, Weirather JL, Pearson RD, Wilson ME, Jeronimo SM: Leishmania infantum chagasi in northeastern Brazil: asymptomatic infection at the urban perimeter. AmJTrop Med Hyg. 2012, 86: 99-107. 10.4269/ajtmh.2012.10-0492.

Caldas AJ, Costa JM, Silva AA, Vinhas V, Barral A: Risk factors associated with asymptomatic infection by Leishmania chagasi in north-east Brazil. Trans R Soc Trop Med Hyg. 2002, 96: 21-28. 10.1016/S0035-9203(02)90227-0.

Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP: Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun. 2003, 71: 6453-6462. 10.1128/IAI.71.11.6453-6462.2003.

Murray HW, Montelibano C, Peterson R, Sypek JP: Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis. 2000, 182: 1497-1502. 10.1086/315890.

Portillo JAC, Feliciano LM, Okenka G, Heizel F, Subauste MC, Subauste C: CD40 and tumour necrosis factor-a co-operate to up-regulate inducuble nitric oxide synthase expression in macrophages. Immunobiol. 2007, 135: 135-150.

Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB: Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol. 2007, 178: 3226-3326.

Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J: Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001, 69: 851-859.

Donhauser N, Pritschet K, Helm M, Harrer T, Schuster P, Ries M, Bischof G, Vollmer J, Smola S, Schmidt B: Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction. PLoS One. 2012, 7: e33925-10.1371/journal.pone.0033925.

Olmo M, Saumoy M, Alonso-Villaverde C, Penaranda M, Gutierrez F, Romeu J, Larrousse M, Curto J, Domingo P, Oteo J, Vila A, Podzamczer D: Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study. HIV Med. 2012, 13: 488-498.

Teixeira MM, Gazzinelli RT, Silva JS: Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol. 2002, 18: 262-265. 10.1016/S1471-4922(02)02283-3.

Gong Y, Hart E, Shchurin A, Hoover-Plow J: Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008, 118: 3012-3024. 10.1172/JCI32750.

Reichel CA, Rehberg M, Bihari P, Moser CM, Linder S, Khandoga A, Krombach F: Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling. J Leukoc Biol. 2008, 83: 864-874. 10.1189/jlb.1007666.

Elmetwali T, Searle PF, McNeish I, Young LS, Palmer DH: CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer. 2010, 9: 52-10.1186/1476-4598-9-52.

Geurts N, Opdenakker G, Van den Steen PE: Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther. 2012, 133: 257-279. 10.1016/j.pharmthera.2011.11.008.

Thông tin
Thông tin xuất bản

BMC Infectious Diseases

Tập 13 Số 1

Thông tin tác giả